FDA 483 - LSNE-Leon, SLU - October 08, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
During a pre-approval inspection, Gadea Biopharma S.L. in León, Spain, was cited for significant discrepancies between its drug application and on-site capabilities, particularly regarding labeling operations. The inspection also revealed a lack of established written procedures for labeling and packaging, and critical issues with the integrity and availability of Certificates of Analysis and their supporting raw data. These findings indicate serious deficiencies in quality control and data management for a contract sterile injectable drug products manufacturer.
ID · de788a02-3087-4f7b-b63f-aa7e59e16731